Pfizer
PFE
1,969 hedge funds and large institutions have $136B invested in Pfizer in 2016 Q1 according to their latest regulatory filings, with 115 funds opening new positions, 919 increasing their positions, 732 reducing their positions, and 92 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 919 | Existing positions reduced: 732
25% more first-time investments, than exits
New positions opened: 115 | Existing positions closed: 92
0.95% more ownership
Funds ownership: 77.07% → 78.02% (+0.95%)
0% less funds holding
Funds holding: 1,970 → 1,969 (-1)
8% less call options, than puts
Call options by funds: $3.49B | Put options by funds: $3.78B
7% less capital invested
Capital invested by funds: $146B → $136B (-$9.65B)
21% less funds holding in top 10
Funds holding in top 10: 253 → 200 (-53)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.62B |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$720M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$717M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$300M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$286M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
-$701M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$471M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$282M |
| 4 |
State Street
Boston,
Massachusetts
|
-$251M |
| 5 |
IG
ING Group
Amsterdam,
Netherlands
|
-$244M |
PFE Hedge Fund Activity: Q1 2016 in Review
1,969 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q1 2016, worth a combined $136B — down 6.6% from $146B a quarter earlier.
Buyers outnumbered sellers: 115 funds opened new PFE positions and 92 closed out — a net gain of 23 holders — while 919 added to existing stakes and 732 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $1.62B. The largest seller was Boston Partners, cutting an estimated $701M.
- 1,969 institutional investors held Pfizer (PFE) as of Q1 2016, down from 1,970 in Q4 2015.
- Funds reported $136B of Pfizer stock for Q1 2016, down 6.6% quarter-over-quarter.
- 115 funds opened new Pfizer positions in Q1 2016 and 92 closed out, a net change of +23 holders.
- The largest Pfizer buyer in Q1 2016 was Goldman Sachs, an estimated $1.62B added.
- The largest Pfizer seller in Q1 2016 was Boston Partners, an estimated $701M sold.
Based on aggregated 13F filings for Q1 2016.